Skip to content
Study details
Enrolling now

Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment

Canadian Cancer Trials Group
NCT IDNCT06235697ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

710

Study length

about 9 years

Ages

18+

Sex

Male only

Locations

46 sites in CA, IL, MO +4

About this study

This trial is testing whether a new way of giving radiation therapy, called SBRT, is as effective as usual radiation therapy for prostate cancer. The treatment involves suppressing testosterone levels with medication (ADT) along with radiation therapy and brachytherapy.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Receive Radiation
  • 2.Receive Radiation SBRT only
  • 3.Take ADT
PhasePhase 3
DrugADT
Primary goalTo compare the progression-free survival (PFS) of SBRT versus conventional EBRT plus brachytherapy boost defined as time to biochemical failure, initiation of salvage therapy, local-regional recurrence, distant progression, or death

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low8%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

hormone therapy

Endpoints

Primary: To compare the progression-free survival (PFS) of SBRT versus conventional EBRT plus brachytherapy boost defined as time to biochemical failure, initiation of salvage therapy, local-regional recurrence, distant progression, or death

Secondary: Economic Outcomes using EQ-5D-5L, Economic Outcomes using FACIT-COST, Overall Survival analysed using a Cox proportional hazards model and graphically described using the Kaplan-Meier method, Participant-reported tolerability using PRO-CTCAE questionnaire, Safety and tolerability assessed by CTCAE v5.0

Procedures

radiation

Body systems

Oncology